Dario Paggiarino Net Worth

The estimated Net Worth of Dario A. Paggiarino is at least $1.58 Million dollars as of 30 March 2024. Dario Paggiarino owns over 50,404 units of EyePoint Pharmaceuticals Inc stock worth over $761,386 and over the last 8 years he sold EYPT stock worth over $0. In addition, he makes $817,165 as Senior Vice President and Chief Medical Officer at EyePoint Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Dario Paggiarino EYPT stock SEC Form 4 insiders trading

Dario has made over 19 trades of the EyePoint Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 50,404 units of EYPT stock worth $414,321 on 30 March 2024.

The largest trade he's ever made was exercising 50,404 units of EyePoint Pharmaceuticals Inc stock on 30 March 2024 worth over $414,321. On average, Dario trades about 9,770 units every 55 days since 2016. As of 30 March 2024 he still owns at least 92,626 units of EyePoint Pharmaceuticals Inc stock.

You can see the complete history of Dario Paggiarino stock trades at the bottom of the page.

Dario Paggiarino biography

Dr. Dario A. Paggiarino M.D. serves as Senior Vice President, Chief Medical Officer of the Company. Dr. Paggiarino has served as our Vice President, Chief Medical Officer since August 2016. Prior to that, Dr. Paggiarino served since April 2013 as Senior Vice President and Chief Development Officer of Lpath, Inc., a biotechnology company focused on the discovery and development of lipidomic-based therapeutic antibodies that target bioactive signaling lipids to treat a wide range of human diseases. Dr. Paggiarino served as Vice President and Therapeutic Unit Head for retina diseases at Alcon, a division of Novartis from 2011 to 2013. He served as Executive Director of Clinical Development and Medical Affairs at Pfizer Global R&D, a division of Pfizer, Inc., from 2001 to 2011. Earlier in his career, he held research and development positions of increasing responsibility at Angelini Pharmaceuticals, Inc., an affiliate of Angelini S.p.A, a privately-owned company, ultimately serving as president and later joined Pharmacia Global R&D, a division of Pharmacia Corporation, where he was clinical program director of ophthalmology.

What is the salary of Dario Paggiarino?

As the Senior Vice President and Chief Medical Officer of EyePoint Pharmaceuticals Inc, the total compensation of Dario Paggiarino at EyePoint Pharmaceuticals Inc is $817,165. There are 2 executives at EyePoint Pharmaceuticals Inc getting paid more, with Nancy Lurker having the highest compensation of $2,079,780.

How old is Dario Paggiarino?

Dario Paggiarino is 63, he's been the Senior Vice President and Chief Medical Officer of EyePoint Pharmaceuticals Inc since 2019. There are 5 older and 12 younger executives at EyePoint Pharmaceuticals Inc. The oldest executive at EyePoint Pharmaceuticals Inc is Goran Ando, 71, who is the Independent Chairman of the Board.

What's Dario Paggiarino's mailing address?

Dario's mailing address filed with the SEC is C/O EYEPOINT PHARMACEUTICALS, INC., 480 PLEASANT STREET, WATERTOWN, MA, 02472.

Insiders trading at EyePoint Pharmaceuticals Inc

Over the last 7 years, insiders at EyePoint Pharmaceuticals Inc have traded over $67,100,515 worth of EyePoint Pharmaceuticals Inc stock and bought 21,910,863 units worth $111,404,456 . The most active insiders traders include Healthcare Partners, L.P.Ew..., Asset Management, Lp Chen B..., and Ye Liu. On average, EyePoint Pharmaceuticals Inc executives and independent directors trade stock every 18 days with the average trade being worth of $1,746,068. The most recent stock trade was executed by Goran Ando on 21 August 2024, trading 5,000 units of EYPT stock currently worth $39,750.

What does EyePoint Pharmaceuticals Inc do?

psivida corp., (nasdaq: psdv) (asx: pva) headquartered in watertown, ma, develops tiny, sustained release, drug delivery products designed to deliver drugs at a controlled and steady rate for months or years. psivida is currently focused on treatment of chronic diseases of the back of the eye utilizing its core technology systems, durasert™ and biosilicon™. the injectable, sustained release micro-insert iluvien® for the treatment of chronic diabetic macula edema (dme), licensed to alimera sciences, inc., has received marketing authorization in austria, france, germany, portugal, the u.k. spain, and italy. iluvien for dme has recently been approved in the us. psivida plans to institute pivotal phase iii clinical trials for the treatment of posterior uveitis with the same micro-insert as iluvien for dme. an investigator-sponsored clinical trial is ongoing for an injectable, bioerodible micro-insert to treat glaucoma and ocular hypertension. psivida's two fda-approved products, retisert®

Complete history of Dario Paggiarino stock trades at EyePoint Pharmaceuticals Inc

EyePoint Pharmaceuticals Inc executives and stock owners

EyePoint Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Nancy Lurker,
  President, Chief Executive Officer, Director
• Nancy S. Lurker,
  Pres, CEO & Director
• Dario Paggiarino,
  Senior Vice President, Chief Medical Officer
• George Elston,
  Chief Financial Officer and Head of Corporate Development
• Dr. Dario A. Paggiarino,
  Sr. VP & Chief Medical Officer
• George O. Elston,
  CFO & Head of Corp. Devel.
• David Scott Jones,
  Sr. VP & Chief Commercial Officer
• Dr. Jay S. Duker M.D.,
  Chief Operating Officer
• Joseph Rayne,
  IR Contact Officer
• Kristine Peterson,
  Independent Director
• David Mazzo,
  Independent Director
• John Landis,
  Independent Director
• David Guyer,
  Independent Director
• Douglas Godshall,
  Independent Director
• Ronald Eastman,
  Independent Director
• Wendy DiCicco,
  Director
• Jay Duker,
  Chief Strategic Scientific Officer
• Said Saim,
  Chief Technology Officer
• Scott Jones,
  Senior Vice President, Chief Commercial Officer
• Ron Honig,
  Senior Vice President, General Counsel, Secretary
• Goran Ando,
  Independent Chairman of the Board
• Dr. Anna Kluczewska,
  CEO of AION Diagnostics Ltd, Pres of AION Diagnostics Ltd and Director of AION Diagnostics Ltd
• Dr. John Weet,
  Sr. VP of Regulatory
• Jennifer Leonard,
  Sr. VP of HR & IT
• Ron I. Honig Esq.,
  Sr. VP, Gen. Counsel & Company Sec.
• Said Saim,
  Chief Technology Officer
• Karen L. Zaderej,
  
• Leonard S Ross,
  See Remarks
• Asset Management, Lp Chen B...,
  
• Anthony P Adamis,
  
• Michael Craig Pine,
  Chief Corp Dev.&Strat. Officer
• Michael W Rogers,
  
• Healthcare Partners, L.P.Ew...,
  
• David Price,
  CFO
• James J Barry,
  Director
• Leonard M Blum,
  See Remarks
• Ramiro Ribeiro,
  Chief Medical Officer
• Ye Liu,
  
• Stuart Duty,
  
• Fred Hassan,